MRES (Institute of Biomedical Research) Current Ratio: 0.00 (As of Dec. 2010)


What is Institute of Biomedical Research Current Ratio?

Institute of Biomedical Research MRES Current Ratio is 0.00 as of Dec. 2010.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Institute of Biomedical Research's current ratio for the quarter that ended in Dec. 2010 was 0.00.

Institute of Biomedical Research has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Institute of Biomedical Research has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Institute of Biomedical Research's Current Ratio or its related term are showing as below:

MRES's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.885
* Ranked among companies with meaningful Current Ratio only.

Institute of Biomedical Research  (OTCPK:MRES) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.

Institute of Biomedical Research Current Ratio Related Terms

Institute of Biomedical Research Current Ratio Historical Data

* Premium members only.

The historical data trend for Institute of Biomedical Research's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Institute of Biomedical Research Current Ratio Chart

Institute of Biomedical Research Annual Data
Trend Dec03 Dec04 Mar06 Mar07 Mar08 Mar09 Mar10
Current Ratio
Get a 7-Day Free Trial 0.48 0.00 0.04 0.01 0.00

Institute of Biomedical Research Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MRES vs HSTC, NTRR, VITIF: Current Ratio Comparison

For the Biotechnology subindustry, Institute of Biomedical Research's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Institute of Biomedical Research Current Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Institute of Biomedical Research's Current Ratio distribution charts can be found below:

* The bar in red indicates where Institute of Biomedical Research's Current Ratio falls into.


Institute of Biomedical Research Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Institute of Biomedical Research's Current Ratio for the fiscal year that ended in Mar. 2010 is calculated as

Current Ratio (A: Mar. 2010 )=Total Current Assets (A: Mar. 2010 )/Total Current Liabilities (A: Mar. 2010 )
=0/0.422
=0.00

Institute of Biomedical Research's Current Ratio for the quarter that ended in Dec. 2010 is calculated as

Current Ratio (Q: Dec. 2010 )=Total Current Assets (Q: Dec. 2010 )/Total Current Liabilities (Q: Dec. 2010 )
=0/0.461
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 0.00 mean?
Institute of Biomedical Research (MRES) has a Current Ratio of 0.00 as of Dec. 2010.
Is Institute of Biomedical Research's Current Ratio too high?
Institute of Biomedical Research's current Current Ratio is 0.00.
How does Institute of Biomedical Research's Current Ratio compare to HSTC and NTRR?
Institute of Biomedical Research's Current Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Current Ratio is 3.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Institute of Biomedical Research's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Institute of Biomedical Research stock overvalued right now?
Institute of Biomedical Research (MRES) has a current Current Ratio of 0.00. The current Current Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Institute of Biomedical Research (MRES), the current Current Ratio is 0.00 as of Dec. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Institute of Biomedical Research Business Description

Address Dubai Science Park, 13th Floor, South Tower, Dubai, ARE, 416452
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based food and medicine and mental health therapeutic research. The company uses brand name M2Bio Sciences engaged in deploying artificial intelligence, science and medicine, clinical research, and emerging technologies.